🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem

<p>Thanks to our partner:Superpower - https://superpower.com</p><p><br></p><p>In episode 75 of Hims House, Jonathan Stern talks with Dr. Alex Tatem, a board-certified urologist who has worked with peptides for 12 years and paid his own way to Silver Spring, MD, to testify on all 7 peptides before the FDA&#39;s Pharmacy Compounding Advisory Committee. The panel overruled the FDA&#39;s own scientists and recommended six of seven for the 503A Bulks List — DSIP the lone no — and Tatem describes what the national media coverage missed: specifically, briefing documents that omitted the peptide data entirely. He explains why the recommendation isn&#39;t binding, why a final rule could take months or years, and how limits on route of administration could hollow out the win. On the business side: why Hims and Noom will wait for final rulemaking while smaller players roll the dice, the API landscape, and the market dynamics of BPC-157 once approved. </p><p><br></p><p>00:00 - Sponsor: Superpower</p><p>01:37 - What it was like in the room of the FDA</p><p>05:53 - Briefing documents OMITTED the data</p><p>11:33 - The one &quot;NO&quot; vote</p><p>17:33 - Why the win isn&#39;t binding</p><p>21:33 - Rulemaking timeline: likely months or years</p><p>24:19 - RFK vs the FDA bureaucracy</p><p>28:06 - Who will sell peptides before final rulemaking</p><p>31:34 - Hims likely won&#39;t </p><p>34:43 - Peptide marketing claims </p><p>40:18 - Every raw material (API) comes from China</p><p>45:23 - BPC under $100 a month? </p><p>48:29 - Where was Ro?</p><p>50:08 - The best argument *against* peptides</p><p>55:12 - Peptides will be an economic gold rush</p><p><br></p><p>Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions. </p>